Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 11/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212773 | 0.97 | FGFR3 (0.54) | FGFR3SRCDRD2DRD4DRD3 | |
| SCHEMBL1126329 | 0.95 | FGFR3 (0.59) | FGFR3SRCDRD2DRD4DRD3 | |
| SCHEMBL1126093 | 0.91 | FGFR3 (0.59) | FGFR3SRCFGFR1FGFR4KDR | |
| SCHEMBL1126395 | 0.90 | FGFR3 (0.55) | FGFR3SRC | |
| SCHEMBL15975451 | 0.87 | FGFR3 (0.56) | FGFR3DRD2DRD4DRD3FGFR1 | |
| SCHEMBL15975453 | 0.85 | FGFR3 (0.56) | FGFR3DRD2DRD4DRD3FGFR1 | |
| SCHEMBL14212766 | 0.84 | FGFR3 (0.66) | FGFR3 | |
| SCHEMBL14212756 | 0.84 | FGFR3 (0.36) | FGFR3SRCFGFR1FGFR4CRHR1 | |
| SCHEMBL14212772 | 0.82 | HPGDS (0.38) | FGFR3SRCFGFR1FGFR4CRHR1 | |
| SCHEMBL14212758 | 0.82 | CRHR1 (0.36) | FGFR3SRCFGFR1FGFR4CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885SRC 58/4885DRD2 4106/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885SRC 58/4885DRD2 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.